Fig. 4From: A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia18F-FDG-PET measured changes of cerebral glucose metabolism (baseline – follow-up) in several AD related brain regions, revealing an improvement or slower decline in the 900-mg group than in the placebo group. p values displayed in the graph are not corrected for multiple comparison, and none survived multiple comparison correctionBack to article page